Press Releases

Webcast ImageStifel 2017 Healthcare Conference (Replay)
11/14/17 at 5:00 p.m. ET
Stifel 2017 Healthcare Conference
Tuesday, November 14, 2017 5:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast Image29th Annual Piper Jaffray Healthcare Conference (Live)
11/28/17 at 10:30 a.m. ET
29th Annual Piper Jaffray Healthcare Conference
Tuesday, November 28, 2017 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12.08.16Zynerba Pharmaceuticals to Host Clinical Research Day on December 15, 2016 to Discuss the Role of ZYN002 CBD Gel in Multiple DiseasesPrinter Friendly Version
12.05.16Zynerba Reports Positive Results for ZYN002 CBD Gel in Phase 1 Studies at 70th Annual Meeting of the American Epilepsy SocietyPrinter Friendly Version
11.28.16Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at the 70th Annual Meeting of the American Epilepsy SocietyPrinter Friendly Version
11.21.16Zynerba Pharmaceuticals to Participate in Upcoming Investor ConferencesPrinter Friendly Version
11.14.16Zynerba Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational HighlightsPrinter Friendly Version
11.09.16Zynerba Pharmaceuticals to Participate in Upcoming Investor ConferencesPrinter Friendly Version
11.02.16Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label Extension Clinical Trial for ZYN002 CBD Gel in Adult Refractory Epilepsy PatientsPrinter Friendly Version
10.17.16Zynerba Provides Clinical Update for Lead Development Candidates – ZYN001 and ZYN002Printer Friendly Version
09.13.16Zynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial OfficerPrinter Friendly Version
09.06.16Zynerba Pharmaceuticals to Participate in Upcoming Investor ConferencesPrinter Friendly Version
09.06.16Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of OsteoarthritisPrinter Friendly Version
08.11.16Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial Results and Organizational ChangesPrinter Friendly Version
08.03.16Zynerba Pharmaceuticals to Present at Canaccord Genuity’s 36th Annual Growth ConferencePrinter Friendly Version
08.01.16Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal SeizuresPrinter Friendly Version
07.06.16Zynerba Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare ConferencePrinter Friendly Version
06.27.16Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal SeizuresPrinter Friendly Version
06.01.16Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and ConferencesPrinter Friendly Version
05.12.16Zynerba Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational HighlightsPrinter Friendly Version
04.12.16Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric FluidPrinter Friendly Version
03.14.16Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational HighlightsPrinter Friendly Version
03.07.16Zynerba Pharmaceuticals to Present at 28th Annual ROTH ConferencePrinter Friendly Version
02.25.16Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X SyndromePrinter Friendly Version
01.06.16Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose TrialPrinter Friendly Version